A socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Roscongress Foundation – a socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 130 economic partners; industrialists’ and entrepreneurs’ unions; and financial, trade, and business associations from 70 countries worldwide.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Aydar Ishmukhametov

Aydar Ishmukhametov

Director General, Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences
Biography
He has graduated (in 1980) the First Moscow State Medical University (Sechenov University), where he later worked (1980-2012).

He is the Candidate of Medical Science (1985) and the Doctor of Medicine (2001).

Since 2013 – the Director General of the Federal State Budgetary Scientific Institution «Chumakov Federal Scientific Center for Research & Development of Immune-and-Biological Product» (FSBSI Chumakov FSC R&D IBP RAS) of the Ministry of Science and Higher Education (Russia). Since 2017 – the head of the subdepartment of the organization and technology of immunobiological preparations production of the First Moscow State Medical University.

Was chosen as the RAS corresponding member in medical sciences department («Pharmacy Organization» specialty) (2016).

Under the leadership of A.A. Ishmukhametov there was developed a unique methodology for the production of information and analytical systems reflecting the actual state of the pharmaceutical industry. It includes the latest statistical data processing techniques and data extrapolation algorithms adapted to the characteristics of the pharmaceutical market. Creation of a fundamentally new analytical content, enabling multifactor analysis and scientific forecasting of economic phenomena in the pharmaceutical market, makes it possible to more effectively solve the problems of the industry. There are formulated and substantiated the basic principles of creating a unified information environment in the field of circulation of medicines.

In 2014, he proposed and implemented the Chumakov Center development concept, which made it possible to combine the scientific, technological and production aspects of creating and introducing into the circulation the original innovative national immunobiological preparations, such as prevention vaccines for the polio, tick-borne encephalitis, yellow fever, which are included in regional immunization calendars. The reorganization of the enterprise’s business processes has carried out with the introduction of quality management principles in biopharmaceutical enterprises. This has made it possible in the shortest possible time to completely modernize the enterprise, obtain a GMP certificate, solve the problems of import substitution and to develop new biopharmaceutical and immunological preparations, some of which have already passed preclinical and clinical studies. As the result, the company has increased its output and exports of the preparations.